CA3233570A1 - Combination therapies of kras g12d inhibitors with sos1 inhibitors - Google Patents
Combination therapies of kras g12d inhibitors with sos1 inhibitorsInfo
- Publication number
- CA3233570A1 CA3233570A1 CA3233570A CA3233570A CA3233570A1 CA 3233570 A1 CA3233570 A1 CA 3233570A1 CA 3233570 A CA3233570 A CA 3233570A CA 3233570 A CA3233570 A CA 3233570A CA 3233570 A1 CA3233570 A1 CA 3233570A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- kras
- alkyl
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252569P | 2021-10-05 | 2021-10-05 | |
| US63/252,569 | 2021-10-05 | ||
| PCT/US2022/045622 WO2023059597A1 (en) | 2021-10-05 | 2022-10-04 | Combination therapies of kras g12d inhibitors with sos1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233570A1 true CA3233570A1 (en) | 2023-04-13 |
Family
ID=85803684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233570A Pending CA3233570A1 (en) | 2021-10-05 | 2022-10-04 | Combination therapies of kras g12d inhibitors with sos1 inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250000863A1 (https=) |
| EP (1) | EP4412718A4 (https=) |
| JP (1) | JP2024537140A (https=) |
| KR (1) | KR20240089358A (https=) |
| CN (1) | CN118382459A (https=) |
| AU (1) | AU2022361380A1 (https=) |
| CA (1) | CA3233570A1 (https=) |
| IL (1) | IL311859A (https=) |
| MX (1) | MX2024004215A (https=) |
| WO (1) | WO2023059597A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| JP2025523101A (ja) * | 2022-07-12 | 2025-07-17 | メッドシャイン ディスカバリー インコーポレイテッド | ピペラジン架橋置換複素環ピリミジン系化合物 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025090811A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Methods of modulating cell proliferation |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217008A1 (en) | 2024-04-08 | 2025-10-16 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| EP4225383A4 (en) * | 2020-10-08 | 2024-12-11 | Kumquat Biosciences Inc. | MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES |
| WO2022217053A1 (en) * | 2021-04-09 | 2022-10-13 | Revolution Medicines, Inc. | Use of sos1 inhibitors with ras inhibitors to treat cancers |
| TW202317589A (zh) * | 2021-07-14 | 2023-05-01 | 美商尼坎醫療公司 | 作為ｋｒａｓ抑制劑的伸烷基衍生物 |
| WO2025085766A1 (en) | 2023-10-20 | 2025-04-24 | Mirati Therapeutics, Inc. | Crystalline forms of fumarate salt of mrtx0902 |
-
2022
- 2022-10-04 AU AU2022361380A patent/AU2022361380A1/en active Pending
- 2022-10-04 CN CN202280077623.1A patent/CN118382459A/zh active Pending
- 2022-10-04 US US18/694,917 patent/US20250000863A1/en active Pending
- 2022-10-04 EP EP22879175.2A patent/EP4412718A4/en active Pending
- 2022-10-04 WO PCT/US2022/045622 patent/WO2023059597A1/en not_active Ceased
- 2022-10-04 KR KR1020247014994A patent/KR20240089358A/ko active Pending
- 2022-10-04 IL IL311859A patent/IL311859A/en unknown
- 2022-10-04 JP JP2024520708A patent/JP2024537140A/ja active Pending
- 2022-10-04 CA CA3233570A patent/CA3233570A1/en active Pending
- 2022-10-04 MX MX2024004215A patent/MX2024004215A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118382459A (zh) | 2024-07-23 |
| WO2023059597A1 (en) | 2023-04-13 |
| IL311859A (en) | 2024-06-01 |
| EP4412718A1 (en) | 2024-08-14 |
| EP4412718A4 (en) | 2025-08-13 |
| JP2024537140A (ja) | 2024-10-10 |
| AU2022361380A1 (en) | 2024-04-11 |
| MX2024004215A (es) | 2024-06-20 |
| US20250000863A1 (en) | 2025-01-02 |
| KR20240089358A (ko) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3233570A1 (en) | Combination therapies of kras g12d inhibitors with sos1 inhibitors | |
| EP4165032B1 (en) | Heteroalkyl dihydroquinoline sulfonamide compounds | |
| CA3112129A1 (en) | Combination therapies | |
| EP2114955B1 (en) | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| EP1341769B1 (en) | Bacterial gyrase inhibitors and uses thereof | |
| EP2079736B1 (en) | Substituted triazoles useful as axl inhibitors | |
| CA3111977A1 (en) | Combination therapies | |
| JP6441947B2 (ja) | キノリンを基にしたキナーゼ阻害剤 | |
| EP3849536A1 (en) | Combination therapies | |
| CA3111980A1 (en) | Combination therapies | |
| JP6402179B2 (ja) | 新規な、ＮＩＫ阻害剤としての１−（４−ピリミジニル）−１Ｈ−ピロロ［３，２−ｃ］ピリジン誘導体 | |
| CA2871715A1 (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| CA2871332A1 (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| CA3158951A1 (en) | 4-substituted aminoisoquinoline derivatives | |
| CN102471337A (zh) | 三唑并吡啶化合物及其作为脯氨酰基羟化酶抑制剂和红细胞生成素产生诱导剂的作用 | |
| JP2010520201A (ja) | ベンズイミダゾール誘導体およびその使用方法 | |
| RS56111B1 (sr) | Ligandi opioidnih receptora i postupci njihove upotrebe i pripreme | |
| TW201008930A (en) | Heterocyclic compounds as factor IXa inhibitors | |
| CA3233567A1 (en) | Combination therapies of kras g12d inhibitors with pan erbb family inhibitors | |
| JP2010520199A (ja) | ピペリジン誘導体およびその使用方法 | |
| TW201111356A (en) | Nitrogen-containing compound and pharmaceutical composition | |
| PH12016500495B1 (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| EP3390393A1 (en) | Alkynyl dihydroquinoline sulfonamide compounds | |
| NZ576950A (en) | Compounds useful as protein kinase inhibitors, particulary PLK1 protein kinases | |
| TW202342019A (zh) | 取代的稠環化合物及其藥物組合物、製備方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241007 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |